Navigation Links
IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
Date:8/4/2008

Featuring Four Keynote Presentations, Four Pre-Conference Summits, Six Therapeutics Conference Topics, Three Post-Conference Workshops and Over

One Hundred and Seventy Exhibitors

WESTBOROUGH, Mass., Aug. 4 /PRNewswire/ -- Today IBC Life Sciences kicks off the 13th Annual Drug Discovery & Development of Innovative Therapeutics (DDT) World Congress in Boston, Massachusetts. 3,000 pharmaceutical, biotechnology, government and academic researchers, executives and technology providers to attend.

The keynote speakers include Elliott Sigal, M.D., Ph.D, from Bristol-Myers Squibb Company and William C. Bertrand, Jr., J.D. Executive Vice President, from MedImmune, Inc. Keynote panel discussions will approach "controversial" topics such as the FDA position on biomarkers and the impact of the 2008 elections on the future of the pharmaceutical/healthcare industry.

The conference sessions will cover six therapeutics areas and four additional drug discovery and development areas: Therapeutic Advances in: Cancer, Cardio-Metabolic, Neurodegeneration, Anti-infectives, Orphan Diseases, Inflammation; Transforming Technologies; Translational Medicine; Next Generation Therapeutics; and R&D Strategies.

The exhibit hall is open on Tuesday, August 5 (10:00 am -7:30 pm) and Wednesday, Aug 6 (10:30 am -5:00 pm). Over 170 drug discovery and development companies will be exhibiting, including 34 new exhibitors and 47 new product launches. Key sponsors of the event include Bend Research Inc., BMG LABTECH, CambridgeSoft Corporation, ChemAxon, ForteBio, Merck, and Tata Consultancy Services.

For additional details visit http://www.drugdisc.com.

About IBC Life Sciences

IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com.

Contact: Keri Dostie

IBC Life Sciences

508-614-1404

kdostie@ibcusa.com


'/>"/>
SOURCE IBC Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis Market ... (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, ... is expected to reach USD 2.20 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:12/8/2016)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... immunotherapies, today announced financial results for the fiscal ... delivering on our commitment to address an unmet ... are pleased with the early clinical response data ... are focused on advancing our lead program – ...
(Date:12/8/2016)... 8, 2016  Renova™ Therapeutics, a biotechnology company ... and type 2 diabetes, announced that it has ... virus (AAV) vector developed in the laboratory of ... Stanford University. The company plans to use this ... product pipeline. "Early research has ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
Breaking Biology Technology:
(Date:12/8/2016)... -- Market Research Future published a half cooked research report on ... and Service Market is expected to grow over the CAGR of ... ... Mobile Biometric Security and Service Market is increasing ... authentication and security from unwanted cyber threats. The increasing use of ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
(Date:12/7/2016)... , December 7, 2016 According to a new market ... Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region ... to grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by ... Continue Reading ... MarketsandMarkets ...
Breaking Biology News(10 mins):